newsfilter
← Earnings
Earnings Releases·

Iambic Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Collaboration revenue was $11.4 million for the third quarter of 2026, compared to $4.7 million for the same period in 2025.
    • Year-to-date (through Q3 2026) collaboration revenue was approximately $24 million, compared to $8.6 million for the same period in 2025.
    • Billings from collaborations were approximately $100 million year-to-date 2026, compared to $19.0 million for the same period in 2025.
    • Research and development expenses were $34.1 million for the third quarter of 2026, compared to $23.1 million for the third quarter of 2025.
    • General and administrative expenses were $7.4 million for the third quarter of 2026, compared to $4.3 million for the third quarter of 2025.
    • Total operating expenses were $41.5 million for the third quarter of 2026, compared to $27.3 million for the third quarter of 2025.
    • Net loss was $38.5 million for the third quarter of 2026, compared to $21.5 million for the third quarter of 2025.
    • Net loss for the third quarter of 2026 included a $10.4 million non-cash charge related to the change in fair value of convertible notes.
    • Costs related to compute were less than $10 million for the year-to-date period through Q3 2026.
    • Cash and cash equivalents were $252.0 million as of September 30, 2026.
    • Pro-forma cash and cash equivalents as of September 30, 2026, were approximately $455 million, including $156 million in IPO net proceeds and $47 million in AbbVie upfront payments received in October 2026.
    • Deferred revenue increased to $96.1 million ($45.8 million current, $50.3 million non-current) as of September 30, 2026, from $20.4 million ($11.3 million current, $9.1 million non-current) as of December 31, 2025.
    • Accounts receivable and unbilled receivables were $55.8 million as of September 30, 2026, compared to $1.3 million as of December 31, 2025.
    • Convertible notes were $76.9 million as of September 30, 2026, compared to $0 as of December 31, 2025.
  • Business Segments and Product Lines:

    • Launched Enchant v3, a 41-billion-parameter transformer model for drug discovery and development.
    • IAM1363 (HER2) Phase 1/2 data presented at ESMO 2026 showed a 36% best overall response rate (systemic) and 41% best overall response rate (intracranial) in heavily pretreated patients.
    • 15 participants in the IAM1363 study remained on treatment for at least 6 months.
    • IAM1363 registrational trial is planned for 2027, subject to regulatory approval.
    • Submitted IND and received a Safe-to-Proceed Letter from the FDA for the IAM217 (KIF18A) Phase 1/2 trial.
    • IND submission for IAM-C1 (CDK2/4) is on track for Q4 2026.
    • IAM217 preclinical data showed approximately 90% regression in an intracranial tumor model.
    • IAM-C1 is designed to avoid CDK1, CDK6, CDK7, and CDK9.
    • Advancing multiple wholly owned discovery programs against hard-to-drug targets in oncology, metabolic, and endocrine diseases.
  • Market and Competitive Landscape:

    • Signed AI discovery collaborations with Bayer and AbbVie, bringing the total number of partnerships signed since 2024 to eight.
    • Achieved a program milestone in the Takeda collaboration in Q3 2026, triggering a $1.0 million payment nine months after the partnership announcement.
    • Continuing work with Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, NVIDIA, and Lambda.
    • Management states that collaborations with AbbVie, Bayer, and Takeda reflect growing industry demand for AI-driven drug discovery.
  • Management Commentary and Tone:

    • CEO Tom Miller, PhD, stated the company's mission is to make better technology for better medicines and that recent months demonstrated this across every part of the business.
    • Management highlighted the intracranial activity and tolerability of IAM1363 and the launch of Enchant v3 as significant advances.
    • Management noted that partnership payments have been an efficient way to fund the company while serving the industry.
    • Management expressed confidence that the IPO provides resources to advance the pipeline through major inflection points and scale the platform.
  • Other Key Points:

    • Closed IPO in October 2026, selling 10,781,250 shares at $16.00 per share, including the full exercise of the underwriters' option.
    • Gross proceeds from the IPO were $172.5 million, with net proceeds of approximately $156.0 million.
    • Common stock began trading on the Nasdaq Global Select Market under the ticker "IAM" on October 15, 2026.
    • Samit Hirawat, MD, joined the Board of Directors in August 2026.
    • William (Bill) Rastetter, PhD, was named Chairperson of the Board.
    • Sunny Chang, JD, was promoted to General Counsel.
    • Moving headquarters to a 121,000-square-foot facility in the Torrey Pines area of San Diego beginning November 2026.
    • Participating in the Jefferies Global Healthcare Conference (November 16-19, 2026), Citi Global Healthcare Conference (December 1-3, 2026), and J.P. Morgan Healthcare Conference (January 11-14, 2027).
Company
IAMBIC THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology